通过抗炎治疗减轻帕克利塔塞尔的阳性效应
Mengwei Zhang1, Saran Lotfollahzadeh1, Nagla Elzinad1
1Department of Medicine, Renal Section, Boston University School of Medicine, Boston, MA, USA.
Vascular medicine (London, England)
|April 16, 2024
概括
帕克利塔克塞尔 (PTX) 增加了炎症媒介,增加了血管并发症的风险. 甲 (DEX) 有效地抵消了这些PTX诱导的变化,这表明了潜在的临床益处.
科学领域:
- 心血管生物学 心血管生物学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕克利塔塞尔 (PTX) 是一种重要的化疗和内血管药物.
- 包括PTX在内的化疗剂越来越多地与心脏瘤学中的血管并发症有关.
- 了解PTX对血管炎症的影响至关重要.
研究的目的:
- 为了研究系统性帕克利塔克塞尔 (PTX) 给药引起的炎症反应.
- 使用RNAseq. 识别PTX诱导的内皮细胞 (EC) 中的转录变化.
- 评估德克萨米他 (DEX) 在减轻PTX诱导的炎症效应方面的疗效.
主要方法:
- 用PTX和DEX治疗的初级人类ECs的RNAseq分析.
- 在体外评估单细胞化学吸引蛋白-1 (MCP-1) 在EC介质中的水平.
- 在小鼠体内研究以评估PTX对血液和大动脉炎症介质的影响.
主要成果:
- 在人体EC中,PTX显著上调促进炎症的调解剂 (MCP-1,CD137),DEX的作用是逆转的.
- 在体外,PTX在EC介质中增加了MCP-1;DEX使水平正常化.
- 在体内,PTX提高了血液和大动脉MCP-1,CD137和其他动脉血介质.
结论:
- 暴露在PTX上调节了动脉血中介的作用.
- 同时使用DEX可以缓解PTX诱导的炎症反应.
- 需要进一步研究PTX疗法的全身效应和DEX的临床作用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160


